You are now searching through our whole database. To make more specific queries, you can use our menu or go directly to papers, companies, trials, or events.
In the bustling neighbourhood of Washington Heights, New York, Alexandra Cohen learned the true value of community and the importance of giving back. From her mother's acts of kindness to the neighbours, she understood that change starts with one person. Today, that core belief drives the Steven & Alexandra Cohen Foundation's philanthropic endeavours across the United States.
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
This phase I/II trial (n=56) will study the safety and side effects of psilocybin in combination with therapy for treating cancer-related anxiety in patients with metastatic cancer. Psilocybin is being studied to treat anxiety or depression in patients with advanced cancer. Participants will receive psilocybin orally and participate in group and individual therapy sessions.
Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: A randomized, prospective, double blind, active placebo-controlled trial
This randomized double-blind, active placebo-controlled trial (n=24) investigates the analgesic efficacy of esketamine on fibromyalgia pain. The study found short-term pain reduction in the ketamine group but no significant differences in treatment effects on pain scores during the 2.5-hour or the 8-week follow-up, suggesting that a short-term infusion of ketamine is insufficient for long-term analgesic effects in fibromyalgia patients.
This trial is registered with the Dutch trial registry that has been offline for over a year and hasn't been registered in any other database. We will update this record once it becomes available. All data are estimates.
This Phase I open-label trial (n=14) studied the safety of psilocybin when administered to healthy participants enrolled in a psychedelic-assisted therapy training program. Participants ingested 25 mg of psilocybin extract, and vital signs, including heart rate, blood pressure, temperature, and ECG, were monitored throughout the study.
Case report: Prolonged amelioration of mild red-green color vision deficiency following psilocybin mushroom use
This case presentation (n=1) describes a subject with red-green colour vision deficiency (mild deuteranomaly) who experienced a partial improvement in their condition after using 5g of dried psilocybin mushrooms. Self-reported Ishihara Test data showed the improvement peaking at 8 days and lasting at least 16 days post-administration, although further observations were confounded by other substance use.
Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers
This single-blind, placebo-controlled, crossover study (n=6) assessed the psychological effects and tolerability of ayahuasca (35, 52.5, 75mg DMT/70kg) in healthy male volunteers with prior experience. The study found dose-dependent increases in various psychological effects, with the tea being well-tolerated from a cardiovascular perspective, though modified physical sensations and nausea were the most frequently reported somatic-dysphoric effects. Ayahuasca induced changes in perceptual, affective, cognitive, and somatic spheres, with stimulatory and visual psychoactive effects of longer duration and milder intensity than intravenously administered DMT.
How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change
This re-analysis of the psilocybin (25mg) versus escitalopram (antidepressant, 6 weeks) RCT finds that in the psilocybin arm, experiential avoidance reductions led to improvements in mental health outcomes (e.g. depression severity). Note: the trial itself was insignificant on the primary measure of depression.
Dosing and Therapeutic Conduct in Administration Sessions in Substance-Assisted Psychotherapy: A Systematized Review
This systematized review (s=82) examines the current evidence for best therapeutic practices during administration sessions with serotonergic psychedelics and entactogens (e.g. MDMA) as adjuncts to psychotherapy. The study finds that the effects of different therapeutic models, methods, techniques, and more complex interventions on therapeutic outcomes have not been investigated rigorously, with most available evidence being anecdotal.
Find everything on psychedelics as medicine. This page allows you to search through our whole database, from research papers to news articles, and from clinical trials to academic articles.
Next to our databases, don’t forget to check out our reports. The reports bring together the separate pieces of information from our database entries into written reports.